These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J; J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762 [TBL] [Abstract][Full Text] [Related]
3. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Siegfried N; Uthman OA; Rutherford GW Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364 [TBL] [Abstract][Full Text] [Related]
4. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855 [TBL] [Abstract][Full Text] [Related]
5. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618 [TBL] [Abstract][Full Text] [Related]
6. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Plettenberg A; Brockmeyer NH; Haastert B; Michalik C; Dupke S; Schewe K; Rausch M; Hower M; Ulmer A; Wolf E; Lorenzen T; Arendt G; Jansen K; Infection; 2011 Feb; 39(1):3-12. PubMed ID: 21221704 [TBL] [Abstract][Full Text] [Related]
7. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852 [TBL] [Abstract][Full Text] [Related]
8. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3. Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G; Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648 [TBL] [Abstract][Full Text] [Related]
10. Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong. Wong KH; Chan KC; Cheng KL; Chan WK; Kam KM; Lee SS AIDS Patient Care STDS; 2007 Feb; 21(2):106-15. PubMed ID: 17328660 [TBL] [Abstract][Full Text] [Related]
11. Mortality and progression to AIDS after starting highly active antiretroviral therapy. van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F; AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280 [TBL] [Abstract][Full Text] [Related]
12. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients. Ho C; Lee S; Wong Kh; Cheng L; Lam M HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862 [TBL] [Abstract][Full Text] [Related]
13. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Palella FJ; Deloria-Knoll M; Chmiel JS; Moorman AC; Wood KC; Greenberg AE; Holmberg SD; Ann Intern Med; 2003 Apr; 138(8):620-6. PubMed ID: 12693883 [TBL] [Abstract][Full Text] [Related]
14. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? Pettit AC; Jenkins CA; Stinnette SE; Rebeiro PF; Blackwell RB; Raffanti SP; Shepherd BE; Sterling TR J Acquir Immune Defic Syndr; 2011 Aug; 57(4):305-10. PubMed ID: 21423024 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538 [TBL] [Abstract][Full Text] [Related]
16. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P; HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287 [TBL] [Abstract][Full Text] [Related]
17. When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. Schomaker M; Egger M; Ndirangu J; Phiri S; Moultrie H; Technau K; Cox V; Giddy J; Chimbetete C; Wood R; Gsponer T; Bolton Moore C; Rabie H; Eley B; Muhe L; Penazzato M; Essajee S; Keiser O; Davies MA; PLoS Med; 2013 Nov; 10(11):e1001555. PubMed ID: 24260029 [TBL] [Abstract][Full Text] [Related]
18. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544 [TBL] [Abstract][Full Text] [Related]
19. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. Estrella MM; Parekh RS; Abraham A; Astor BC; Szczech LA; Anastos K; Dehovitz JA; Merenstein DJ; Pearce CL; Tien PC; Cohen MH; Gange SJ J Acquir Immune Defic Syndr; 2010 Oct; 55(2):217-20. PubMed ID: 20581688 [TBL] [Abstract][Full Text] [Related]